Maybe you should look at is as an incorrect bear.
No reverse split was advised. As bears thought it would if the maa was rejected.
Advent was acquired by NWBO for an unbelievably reasonable sum. As bears did not think would happen.
The C-lab suite is under construction for anticipated increased scale up after commercialization. Bears forget, there is no other imminent DCvax commercial product, absolutely nothing that would cause this demand near term other than the current MAA succeeding.
Sometime in late Sept or early October, Dr. Ashkan thought an MHRA MAA decision on DCVax-l would/will be upon us in a “couple months.”
The authorized share level was increased by 900 million.
Typically CEOs are informed by regulatory agencies at necessary stages so that the company can execute its next critical preparations.
You are left with, either LP is bluffing or they are getting ready because it’s happening.
Market Data 
Markets 
AI
